List | Section | Observation |
---|---|---|
PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines | No observations |
WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Others observations: Therapeutic alternatives: - 4th level ATC chemical subgroup (C09CA Angiotensin II receptor blockers (ARBs), plain) (for telmisartan) - chlorthalidone, chlorothiazide, indapamide (for hydrochlorothiazide) |
List | Section | Observation |
---|---|---|
PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines | No observations |
WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Others observations: Therapeutic alternatives: - 4th level ATC chemical subgroup (C09CA Angiotensin II receptor blockers (ARBs), plain) (for telmisartan) - chlorthalidone, chlorothiazide, indapamide (for hydrochlorothiazide) |
List | Section | Observation |
---|---|---|
PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines | No observations |
WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Others observations: Therapeutic alternatives: - 4th level ATC chemical subgroup (C09CA Angiotensin II receptor blockers (ARBs), plain) (for telmisartan) - chlorthalidone, chlorothiazide, indapamide (for hydrochlorothiazide) |